Search

Displaying results 5611 - 5620 of 7186 in total
  1. Drug

    Amilomotide

    go.drugbank.com/drugs/DB05150
    Investigational

    It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.

  2. Drug

    Metyrapone

    go.drugbank.com/drugs/DB01011
    ApprovedInvestigational

    An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.

  3. Drug

    Foretinib

    go.drugbank.com/drugs/DB12307
    Investigational

    Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer.

  4. Drug

    APT3111

    go.drugbank.com/drugs/DB06390
    Experimental

    APT3111 is an investigational drug used to treat PNH (paroxysmal nocturnal haemoglobinurea).

  5. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    Covax-19™ was tested in animal studies, and shown to achieve potent antibody and T-cell responses against the COVID-19 spike protein. … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).

  6. Drug

    Ginsenoside Rg1

    go.drugbank.com/drugs/DB06750
    ExperimentalNutraceutical

    Because ginsenosides appear to affect multiple pathways, their effects are complex and difficult to isolate. Rg1 Appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng).

  7. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    This drug was developed by Schering-Plough.

  8. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects. … R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence.

  9. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]

  10. Drug

    Litifilimab

    go.drugbank.com/drugs/DB18864
    Investigational

    SCLE) And/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory And/or Intolerant to Antimalarial Therapy). … Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (